BBOT Reports Progress on Three Clinical Programs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
"In the first quarter, we reported meaningful progress across all three clinical programs, including encouraging preliminary antitumor activity and a potentially differentiated safety profile for BBO-8520 in lung cancer; anti-tumor activity and a partial response (PR) in pancreatic cancer with BBO-11818 as monotherapy; and confirmation of full target engagement without hyperglycemia for BBO-10203," said Pedro J. Beltran, PhD, Chief Executive Officer of BBOT. "In addition, we announced the publication of BBO-11818 in Cancer Discovery, highlighting its role as a potent and selective pan-KRAS inhibitor. These results and our cash runway into 2028 position us well as we continue advancing our differentiated pipeline to provide new treatment options for patients with limited choices."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBOT
Wall Street analysts forecast BBOT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.550
Low
18.00
Averages
22.83
High
27.00
Current: 8.550
Low
18.00
Averages
22.83
High
27.00
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BridgeBio Oncology Reports Q1 Earnings and Cash Position
- Earnings Report: BridgeBio Oncology's Q1 GAAP EPS stands at -$526.11, indicating significant challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of March 31, 2026, BridgeBio holds $388.9 million in cash, cash equivalents, and marketable securities, which is expected to provide a cash runway into 2028, ensuring continued investment in R&D.
- Market Reaction: Despite the poor Q1 earnings report, BridgeBio's stock rose due to its pancreatic cancer asset receiving Fast Track status, reflecting market optimism regarding its potential treatment solutions.
- Future Outlook: The company is at a pivotal moment with the KRAS revolution; although current financial performance is lacking, its strategic positioning in oncology may drive future growth opportunities.
See More
BridgeBio Oncology Reports Encouraging Clinical Data and Financial Results
- Clinical Data Progress: BridgeBio Oncology has reported encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs, particularly with BBO-11818 achieving a 56% tumor reduction in pancreatic cancer patients, indicating its potential as a potent and selective pan-KRAS inhibitor.
- Strong Financial Position: As of March 31, 2026, BBOT reported cash and cash equivalents totaling $388.9 million, which is expected to fund operations into 2028, demonstrating financial resilience for ongoing R&D and market expansion.
- Increased R&D Expenses: The first quarter of 2026 saw R&D expenses rise to $39.8 million from $20.6 million in the same quarter of 2025, primarily due to increased clinical trial and manufacturing costs, reflecting the company's commitment to advancing its innovative drug pipeline.
- Executive Changes: On April 20, 2026, Pedro J. Beltran, PhD, was appointed CEO, and Neil Kumar, PhD, became Executive Chairman of the Board, indicating a strategic leadership shift aimed at driving future business growth and innovation.
See More
Key Wall Street Rating Updates for Monday
- Micron Buy Rating: D.A. Davidson reiterates its buy rating on Micron with a target price of $1,000, expressing strong confidence in the company's future amidst a recovering memory industry, which could significantly boost its stock performance.
- Starz Entertainment Upgrade: Baird upgrades Starz Entertainment from neutral to outperform, citing its favorable market position following its separation from the studio, which is expected to drive future growth and enhance investor confidence.
- Dell Downgrade to Neutral: UBS downgrades Dell from buy to neutral primarily on valuation grounds, noting that the stock's 170% rise over the past year has balanced the risk/reward profile, potentially affecting future investment decisions.
- Tesla Overweight Reiteration: Piper Sandler reiterates its overweight rating on Tesla, highlighting a range of positive tailwinds expected to drive valuation in the coming years, urging investors to focus on long-term delivery and earnings growth potential.
See More
Emerging Trends in Rare Disease Drug Development
- Patient-Led Innovation: A report from the Chan Zuckerberg Biohub indicates that half of the 20 funded organizations have engaged in clinical trials within five years since 2019, showcasing the significant role of patient groups in driving medical innovation in rare disease drug development.
- Rare Bootcamp Forum: Ultragenyx hosts the Rare Bootcamp twice a year, providing families with essential knowledge and resources for drug development; the recent event in Boston featured over 20 sessions covering the entire drug development spectrum, aiding families in understanding and participating in research.
- Family Support Network: The event not only facilitated direct access to researchers and experts but also fostered experience sharing among families through networking sessions and dinners, enhancing community cohesion and alleviating the isolation often felt by families dealing with rare diseases.
- Future Outlook: Ultragenyx founder Kakkis expressed hope that one day such events will no longer be necessary, indicating that the challenges of rare disease drug development will be resolved, allowing patients to access ready-made treatments, reflecting an optimistic vision for future medical innovation.
See More
BridgeBio Appoints New CEO and COO
- Executive Appointments: BridgeBio Oncology Therapeutics has appointed Pedro J. Beltran as CEO and Idan Elmelech as COO effective April 20, 2026, aiming to strengthen the company's leadership and strategic direction.
- Experienced Leadership: Beltran brings approximately 20 years of oncology R&D experience from previous roles at Amgen and UNITY Biotechnology, which is expected to provide valuable industry insights and drive innovation within the company.
- Former CEO's Advisory Role: Former CEO Eli Wallace will continue as a Senior Adviser, ensuring strategic consistency during the transition and leveraging his extensive experience to guide the new leadership team.
- Financial Performance: BridgeBio Oncology reported a GAAP EPS of -$0.49, and despite facing financial challenges, the company is actively advancing its KRAS revolution plan, demonstrating confidence in future growth prospects.
See More
BBOT Appoints New CEO and COO to Drive Growth
- Leadership Transition: Pedro J. Beltran, PhD, appointed as CEO on April 20, 2026, brings over 20 years of oncology drug development experience to steer BBOT's strategic growth in RAS and PI3Kα malignancies.
- Operational Management Enhancement: Idan Elmelech takes on the role of COO, overseeing finance, corporate strategy, and business development, aiming to accelerate the expansion of BBOT's clinical assets through optimized operational efficiency.
- Board Support: Neil Kumar, PhD, appointed as Executive Chairman, will guide the company into its next development phase, emphasizing that the leadership change will enhance the company's execution capabilities and strategic precision in clinical trials.
- Former CEO's Continued Contribution: Former CEO Eli Wallace, PhD, will serve as a Senior Adviser, leveraging his scientific expertise to support BBOT's projects, ensuring the company's sustained development under new leadership.
See More
BridgeBio Oncology Reports Q1 Earnings and Cash Position
- Earnings Report: BridgeBio Oncology's Q1 GAAP EPS stands at -$526.11, indicating significant challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of March 31, 2026, BridgeBio holds $388.9 million in cash, cash equivalents, and marketable securities, which is expected to provide a cash runway into 2028, ensuring continued investment in R&D.
- Market Reaction: Despite the poor Q1 earnings report, BridgeBio's stock rose due to its pancreatic cancer asset receiving Fast Track status, reflecting market optimism regarding its potential treatment solutions.
- Future Outlook: The company is at a pivotal moment with the KRAS revolution; although current financial performance is lacking, its strategic positioning in oncology may drive future growth opportunities.
See More
BridgeBio Oncology Reports Encouraging Clinical Data and Financial Results
- Clinical Data Progress: BridgeBio Oncology has reported encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs, particularly with BBO-11818 achieving a 56% tumor reduction in pancreatic cancer patients, indicating its potential as a potent and selective pan-KRAS inhibitor.
- Strong Financial Position: As of March 31, 2026, BBOT reported cash and cash equivalents totaling $388.9 million, which is expected to fund operations into 2028, demonstrating financial resilience for ongoing R&D and market expansion.
- Increased R&D Expenses: The first quarter of 2026 saw R&D expenses rise to $39.8 million from $20.6 million in the same quarter of 2025, primarily due to increased clinical trial and manufacturing costs, reflecting the company's commitment to advancing its innovative drug pipeline.
- Executive Changes: On April 20, 2026, Pedro J. Beltran, PhD, was appointed CEO, and Neil Kumar, PhD, became Executive Chairman of the Board, indicating a strategic leadership shift aimed at driving future business growth and innovation.
See More
Key Wall Street Rating Updates for Monday
- Micron Buy Rating: D.A. Davidson reiterates its buy rating on Micron with a target price of $1,000, expressing strong confidence in the company's future amidst a recovering memory industry, which could significantly boost its stock performance.
- Starz Entertainment Upgrade: Baird upgrades Starz Entertainment from neutral to outperform, citing its favorable market position following its separation from the studio, which is expected to drive future growth and enhance investor confidence.
- Dell Downgrade to Neutral: UBS downgrades Dell from buy to neutral primarily on valuation grounds, noting that the stock's 170% rise over the past year has balanced the risk/reward profile, potentially affecting future investment decisions.
- Tesla Overweight Reiteration: Piper Sandler reiterates its overweight rating on Tesla, highlighting a range of positive tailwinds expected to drive valuation in the coming years, urging investors to focus on long-term delivery and earnings growth potential.
See More
Emerging Trends in Rare Disease Drug Development
- Patient-Led Innovation: A report from the Chan Zuckerberg Biohub indicates that half of the 20 funded organizations have engaged in clinical trials within five years since 2019, showcasing the significant role of patient groups in driving medical innovation in rare disease drug development.
- Rare Bootcamp Forum: Ultragenyx hosts the Rare Bootcamp twice a year, providing families with essential knowledge and resources for drug development; the recent event in Boston featured over 20 sessions covering the entire drug development spectrum, aiding families in understanding and participating in research.
- Family Support Network: The event not only facilitated direct access to researchers and experts but also fostered experience sharing among families through networking sessions and dinners, enhancing community cohesion and alleviating the isolation often felt by families dealing with rare diseases.
- Future Outlook: Ultragenyx founder Kakkis expressed hope that one day such events will no longer be necessary, indicating that the challenges of rare disease drug development will be resolved, allowing patients to access ready-made treatments, reflecting an optimistic vision for future medical innovation.
See More
BridgeBio Appoints New CEO and COO
- Executive Appointments: BridgeBio Oncology Therapeutics has appointed Pedro J. Beltran as CEO and Idan Elmelech as COO effective April 20, 2026, aiming to strengthen the company's leadership and strategic direction.
- Experienced Leadership: Beltran brings approximately 20 years of oncology R&D experience from previous roles at Amgen and UNITY Biotechnology, which is expected to provide valuable industry insights and drive innovation within the company.
- Former CEO's Advisory Role: Former CEO Eli Wallace will continue as a Senior Adviser, ensuring strategic consistency during the transition and leveraging his extensive experience to guide the new leadership team.
- Financial Performance: BridgeBio Oncology reported a GAAP EPS of -$0.49, and despite facing financial challenges, the company is actively advancing its KRAS revolution plan, demonstrating confidence in future growth prospects.
See More
BBOT Appoints New CEO and COO to Drive Growth
- Leadership Transition: Pedro J. Beltran, PhD, appointed as CEO on April 20, 2026, brings over 20 years of oncology drug development experience to steer BBOT's strategic growth in RAS and PI3Kα malignancies.
- Operational Management Enhancement: Idan Elmelech takes on the role of COO, overseeing finance, corporate strategy, and business development, aiming to accelerate the expansion of BBOT's clinical assets through optimized operational efficiency.
- Board Support: Neil Kumar, PhD, appointed as Executive Chairman, will guide the company into its next development phase, emphasizing that the leadership change will enhance the company's execution capabilities and strategic precision in clinical trials.
- Former CEO's Continued Contribution: Former CEO Eli Wallace, PhD, will serve as a Senior Adviser, leveraging his scientific expertise to support BBOT's projects, ensuring the company's sustained development under new leadership.
See More
